Effects of chronic sazetidine-A, a selective α4β2 neuronal nicotinic acetylcholine receptors desensitizing agent on pharmacologically-induced impaired attention in rats
- 306 Downloads
Nicotine and nicotinic agonists have been shown to improve attentional function. Nicotinic receptors are easily desensitized, and all nicotinic agonists are also desensitizing agents. Although both receptor activation and desensitization are components of the mechanism that mediates the overall effects of nicotinic agonists, it is not clear how each of the two opposed actions contributes to attentional improvements. Sazetidine-A has high binding affinity at α4β2 nicotinic receptors and causes a relatively brief activation followed by a long-lasting desensitization of the receptors. Acute administration of sazetidine-A has been shown to significantly improve attention by reversing impairments caused by the muscarinic cholinergic antagonist scopolamine and the NMDA glutamate antagonist dizocilpine.
In the current study, we tested the effects of chronic subcutaneous infusion of sazetidine-A (0, 2, or 6 mg/kg/day) on attention in Sprague-Dawley rats. Furthermore, we investigated the effects of chronic sazetidine-A treatment on attentional impairment induced by an acute administration of 0.02 mg/kg scopolamine.
During the first week period, the 6-mg/kg/day sazetidine-A dose significantly reversed the attentional impairment induced by scopolamine. During weeks 3 and 4, the scopolamine-induced impairment was no longer seen, but sazetidine-A (6 mg/kg/day) significantly improved attentional performance on its own. Chronic sazetidine-A also reduced response latency and response omissions.
This study demonstrated that similar to its acute effects, chronic infusions of sazetidine-A improve attentional performance. The results indicate that the desensitization of α4β2 nicotinic receptors with some activation of these receptors may play an important role in improving effects of sazetidine-A on attention.
KeywordsNicotinic receptors Scopolamine Animal model Cognition
This study was supported by the NIDA U19 grant DA027990. Georgetown University holds a patent for sazetidine-A.
- Bartus RT, Dean RL, Flicker C (1987) Cholinergic psychopharmacology: an integration of human and animal research on memory. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven, New York, pp 219–232Google Scholar
- Cincotta SL, Yorek MS, Moschak TM, Lewis SR, Rodefer JS (2008) Selective nicotinic acetylcholine receptor agonists: potential therapies for neuropsychiatric disorders with cognitive dysfunction. Curre Opin Investig Drugs 9:47–56Google Scholar
- Dunbar G, Boeijinga PH, Demazieres A, Cisterni C, Kuchibhatla R, Wesnes K, Luthringer R (2007) Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacology 191:919–929PubMedCrossRefGoogle Scholar
- Johnson JE, Slade S, Wells C, Petro A, Sexton H, Rezvani AH, Brown ML, Paige MA, McDowell BE, Xiao Y, Kellar KJ, Levin ED (2012) Chronic sazetidine-A infusion reduces nicotine self-administration in male and female rats. Psychopharmacology 222:269–276Google Scholar
- Levin ED, Cauley M, Rezvani AH (2012) Improvement of attentional function with antagonism of nicotinic receptors. Eur J Pharmacol (in press)Google Scholar
- Levin ED, Rezvani AH, Xiao Y, Slade S, Cauley M, Wells D, Hampton D, Petro A, Rose JE, Brown ML, Paige MA, McDowell BE, Kellar K (2010) Sazetidine-A, a selective α4β2 nicotinic receptor desensitizing agent and partial agonist reduces nicotine self-administration in rats. J Pharmacol Exp Ther 332:933–939PubMedCrossRefGoogle Scholar
- Levin ED, Simon BB, Conners CK (1998b) Transdermal nicotine treatment of attention deficit/hyperactivity disorder. In: Arneric SP, Brioni JD (eds) Neuronal nicotinic receptors: pharmacology and therapeutic opportunities. Wiley, New York, pp 349–357Google Scholar
- Lomazzo E, Hussmann GP, Turner JR, Blendy JA, Rezvani AH, Deguisto DM, Xiao Y1, Levin ED, Perry DC, Kellar K (2011) Effects of sazetidine-A on neuronal nicotinic receptor density in rodent brain. Presented at the 41th Annual Meeting of the Society for Neuroscience, Washington DCGoogle Scholar
- Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R (2006) Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63:630–638PubMedCrossRefGoogle Scholar
- Rezvani AH, Cauley M, Sexton H, Xiao X, Brown ML, Paige MA, McDowell BE, Kellar KL, Levin ED (2011) Sazetidine-A, a selective α4β2 nicotinic acetylcholine receptor desensitizing agent reverses dizocilpine and scopolamine-induced attentional impairments in rats. Psychopharmacology 215:621–630PubMedCrossRefGoogle Scholar
- Rezvani AH, Slade S, Wells C, Petro A, Li TK, Lumeng L, Xiao Y, Brown ML, Paige MA, McDowell BE, Kellar KJ, Rose JE, Levin ED (2010) Sazetidine-A, a selective α4β2 nicotinic acetylcholine receptor desensitizing agent and partial agonist reduces both alcohol and nicotine self-administration in selectively-bred alcohol preferring (P) rats. Psychopharmacology 211:161–174PubMedCrossRefGoogle Scholar
- Rezvani AH, Tizabi Y, Getachew B, Hauser SR, Caldwell DP, Hunter C, Levin ED (2008b) Chronic nicotine and dizocilpine effects on nicotinic and NMDA glutamatergic receptor regulation: interactions with clozapine actions and attentional performance in rats. Prog Neuropsychopharmacology Biol Psychiat 32:1030–1040CrossRefGoogle Scholar
- Snedecor GW, Cochran WG (1967) Statistical methods. Iowa State University Press, AmesGoogle Scholar
- Terry AV Jr, Risbrough VB, Buccafusco JJ, Menzaghi F (2002) Effects of (+/−)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A), a selective ligand for nicotinic acetylcholine receptors, in tests of visual attention and distractibility in rats and monkeys. J Pharmacol Exp Ther 301:284–292PubMedCrossRefGoogle Scholar
- Wilens TE, Biederman J, Spencer TJ, Bostic J, Prince J, Monuteaux MC, Soriano J, Fine C, Abrams A, Rater M, Polisner D (1999) A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Amer J Psychiat 156:1931–1937PubMedGoogle Scholar
- Xiao Y, Yasuda RP, Sahibzada, Wolfe BB, Horton L, Paige M, Brown ML, Kellar KJ (2010) Sazetidine-A selectively induces a long lasting desensitization of α4β2 nicotinic acetylcholine receptors. Society for Neuroscience 40th Annual Meeting, Washington, DCGoogle Scholar
- Xiao Y, Yasuda RP, Sahibzada N, Horton L, DiPietro JR, Iwueze AF, Paige MA, McDowell B, Brown ML, Wolfe BB, Kellar KJ (2008) Pharmacological properties of sazetidine-A, a selective ligand of α4β2 nicotinic acetylcholine receptor. Society for Neuroscience 38th Annual Meeting, Washington, DCGoogle Scholar
- Zwart R, Carbone AL, Moroni M, Bermudez I, Mogg AJ, Folly EA, Broad LM, Williams AC, Zhang D, Ding C, Heinz BA, Sher E (2008) Sazetidine-A is a potent and selective agonist at native and recombinant alpha 4 beta 2 nicotinic acetylcholine receptors. Mol Pharmacol 73:1838–1843PubMedCrossRefGoogle Scholar